new version V2017

Pioglitazone antidiabetic drugs
Description Results

Actos      

  • Group by...

pdf
TrialStudied treatmentControl treatmentpatientsROBResultNCT

diabetes type 2

EC404pioglitazonemetformin Exploratory Negative
EC409pioglitazone + sulfonylureametformin + sulfonylurea Exploratory Negative
PNFP-026pioglitazoneplacebo Exploratory Negative
PNFP-012pioglitazoneplacebo Exploratory Negative
PNFP-001pioglitazoneplacebo Exploratory Negative
PROACTIVEpioglitazoneplacebo - NCT00174993
PNFP-014pioglitazone + insulinplacebo (add on insulin) Exploratory Negative
OPI-502pioglitazone + insulinplacebo (add on insulin) Exploratory Negative
PNFP-027pioglitazone + metforminplacebo (add on MET) Exploratory Negative
GLAIpioglitazonerosiglitazone Exploratory NegativeNCT00331487
PNFP-010pioglitazone + sulfonylureasulfonylurea Exploratory Negative
OPI-504pioglitazonesulfonylurea Exploratory Negative NCT00521820
EC405pioglitazonesulfonylurea Exploratory Negative
OPI-501pioglitazonesulfonylurea Exploratory Negative
OPI-520pioglitazonesulfonylurea Exploratory NegativeNCT00521742
EC410pioglitazone + metforminsulfonylurea + metformin Exploratory Negative
OPI-506pioglitazonesulfonylurea Exploratory NegativeNCT00494312
PROactive, 2005pioglitazoneplacebo Low risk of bias Suggesting NCT00174993
PERISCOPE, 2008pioglitazoneglimepiride Exploratory NegativeNCT00225277
IRIS, 2016pioglitazoneplacebo - NCT00091949
PPAR ongoing pioglitazonestandard glucose-lowering drugs - NCT00212004
linagliptin 1264.3 ongoing linagliptin + pioglitazonepioglitazone - NCT01183013



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons